Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Mixed views among analysts
Last evaluation 55+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Chronological view of analyst recommendations for this asset
The speaker evaluates Novo Nordisk's market performance, its positioning against competitor drug data, and the technical chart outlook.
CNBC TelevisionThe speaker analyzes the company's growth strategy following the obesity pill launch, Medicare coverage expectations, and production volume increase scenarios.
CNBC TelevisionThe impact of a competitor's decision to withdraw a similar weight-loss drug from the market and the company's FDA-backed legal moves on stock performance are examined.
CNBC TelevisionThe speaker analyzes the patent protection of oral semaglutide technology and the impact of regulators' stance against unapproved competitors on the company's market share.
CNBC TelevisionThe speaker analyzes the sharp rise in the company's shares and the strengthening of its market dominance following a competitor's decision to withdraw a product from the market.
CNBC TelevisionThe speaker examines a significant 17% downward movement observed in Novo Nordisk shares.
BloombergHTThe pharmaceutical company's competitive position in the GLP-1 market, pricing strategies, and the potential of new product launches are evaluated.
CNBC TelevisionGuggenheim Managing Director Seamus Fernandez analyzes Novo Nordisk's strategic move with the oral pill form of Wegovy. He examines its potential to recoup market share losses, considering the competitive landscape and the impending launch of Eli Lilly's own oral GLP-1 product, while also acknowledging Novo's existing patient base.
CNBC TelevisionNovo Nordisk's US shares are declining amidst a prediction of a 13% drop in sales for the year, as the company grapples with pricing pressures. However, the discussion also notes the recent approval and strong initial prescription numbers for its new oral obesity medication, presenting a nuanced outlook.
Yahoo FinanceThe speaker evaluates the decline in shares of Ozempic maker Novo Nordisk and the company's warning that sales and profit growth will take a hit due to increased competition. The impacts of lower realized prices and the most-favored-nation agreement in the US are analyzed.
Yahoo FinanceThe speaker examines the stock performance and analyst revisions following the company's new drug approval.
BloombergHTThe speaker evaluates the competition in the obesity drug market and the recent recovery in the company's stock performance.
CNBC TelevisionThe speaker analyzes the competitive position in the pharmaceutical sector and leadership in specific treatment areas.
CNBC TelevisionThe speaker examines the competitive landscape between Eli Lilly and Novo Nordisk in the obesity market, specifically regarding oral medications and market expansion potential.
CNBC TelevisionThe speaker evaluates the potential of the new oral GLP-1 medication to expand the obesity treatment market by overcoming barriers such as needle phobia and cold chain requirements. The analysis covers patient preferences regarding daily pills versus weekly injections and the broader impact on accessibility in markets lacking refrigeration infrastructure.
CNBC TelevisionThe CEO evaluates the launch of the oral Wegovy formulation, highlighting its 16.6% weight loss efficacy comparable to injectables and additional cardiovascular benefits, while addressing pricing strategies to improve market access.
CNBC TelevisionThe CEO analyzes the development process of the company's new oral weight loss drug and its market accessibility compared to injections.
CNBC TelevisionEvaluates the stock's bearish to bullish reversal and signs of life, projecting significant upside.
CNBC TelevisionThe speaker examines the approved oral weight loss medication and the impact of GLP-1 market growth on consumer spending.
Yahoo FinanceThe speaker emphasizes that the stock has turned from bottom levels and should be included in long-term portfolios.
BloombergHTThe speaker evaluates Novo Nordisk's market performance, its positioning against competitor drug data, and the technical chart outlook.
* Does not constitute investment advice
The speaker analyzes the company's growth strategy following the obesity pill launch, Medicare coverage expectations, and production volume increase scenarios.
* Does not constitute investment advice
The impact of a competitor's decision to withdraw a similar weight-loss drug from the market and the company's FDA-backed legal moves on stock performance are examined.
* Does not constitute investment advice
The speaker analyzes the patent protection of oral semaglutide technology and the impact of regulators' stance against unapproved competitors on the company's market share.
* Does not constitute investment advice
The speaker analyzes the sharp rise in the company's shares and the strengthening of its market dominance following a competitor's decision to withdraw a product from the market.
* Does not constitute investment advice
The speaker examines a significant 17% downward movement observed in Novo Nordisk shares.
* Does not constitute investment advice
The pharmaceutical company's competitive position in the GLP-1 market, pricing strategies, and the potential of new product launches are evaluated.
* Does not constitute investment advice
Guggenheim Managing Director Seamus Fernandez analyzes Novo Nordisk's strategic move with the oral pill form of Wegovy. He examines its potential to recoup market share losses, considering the competitive landscape and the impending launch of Eli Lilly's own oral GLP-1 product, while also acknowledging Novo's existing patient base.
* Does not constitute investment advice
Novo Nordisk's US shares are declining amidst a prediction of a 13% drop in sales for the year, as the company grapples with pricing pressures. However, the discussion also notes the recent approval and strong initial prescription numbers for its new oral obesity medication, presenting a nuanced outlook.
* Does not constitute investment advice
The speaker evaluates the decline in shares of Ozempic maker Novo Nordisk and the company's warning that sales and profit growth will take a hit due to increased competition. The impacts of lower realized prices and the most-favored-nation agreement in the US are analyzed.
* Does not constitute investment advice
The speaker examines the stock performance and analyst revisions following the company's new drug approval.
* Does not constitute investment advice
The speaker evaluates the competition in the obesity drug market and the recent recovery in the company's stock performance.
* Does not constitute investment advice
The speaker analyzes the competitive position in the pharmaceutical sector and leadership in specific treatment areas.
* Does not constitute investment advice
The speaker examines the competitive landscape between Eli Lilly and Novo Nordisk in the obesity market, specifically regarding oral medications and market expansion potential.
* Does not constitute investment advice
The speaker evaluates the potential of the new oral GLP-1 medication to expand the obesity treatment market by overcoming barriers such as needle phobia and cold chain requirements. The analysis covers patient preferences regarding daily pills versus weekly injections and the broader impact on accessibility in markets lacking refrigeration infrastructure.
* Does not constitute investment advice
The CEO evaluates the launch of the oral Wegovy formulation, highlighting its 16.6% weight loss efficacy comparable to injectables and additional cardiovascular benefits, while addressing pricing strategies to improve market access.
* Does not constitute investment advice
The CEO analyzes the development process of the company's new oral weight loss drug and its market accessibility compared to injections.
* Does not constitute investment advice
Evaluates the stock's bearish to bullish reversal and signs of life, projecting significant upside.
* Does not constitute investment advice
The speaker examines the approved oral weight loss medication and the impact of GLP-1 market growth on consumer spending.
* Does not constitute investment advice
The speaker emphasizes that the stock has turned from bottom levels and should be included in long-term portfolios.
* Does not constitute investment advice